Yahoo! Finance - Eurofins & Transplant Genomics Launch OmniGraf™ Kidney Rejection Biomarker
OmniGraf™ – the first and only rejection assay on the market that combines the power of gene expression profiling (TruGraf®) and donor-derived cell-free DNA (Viracor TRAC®) in one non-invasive, easy-to-draw test. OmniGraf offers the highest positive predictive value (PPV) and negative predictive value (NPV) of any kidney test available, empowering clinicians and patients to make the best possible treatment decisions with the goal of improving long-term graft outcomes.
360 Dx - Eurofins Viracor Test Measures T-Cell Response to Determine COVID-19 Immunity
NEW YORK – While vaccines for SARS-CoV-2 have rolled out at home and abroad, there is still uncertainty about their long-term effectiveness against the virus, and questions linger about whether a booster shot will be necessary and how often individuals will need to get vaccinated to remain protected against the virus. Against this backdrop Eurofins Viracor has developed a test ...
Eurofins Viracor Invests in Innovation with the Launch of Coronavirus (COVID-19) SARS-CoV-2 inSIGHT™ T Cell Immunity Testing
As one of the first commercial labs to deliver COVID-19 testing, Eurofins Viracor, Inc. continues to invest in innovation with the launch of Coronavirus SARS-CoV-2 inSIGHT™ T Cell Immunity testing. Viracor’s inSIGHT™ T Cell Immunity test delivers a deeper understanding of a patient's response to viral antigens and gives healthcare providers critical insight to aid in treatment ...
Eurofins' US Transplant Diagnostics and Cleveland Clinic Sign a Licensing Agreement to Expand Access to an Innovative, Novel Biomarker for Detecting Rejection in Kidney Transplant Patients
Urine biomarker test will provide healthcare practitioners with a highly accurate, non-invasive tool to identify and monitor rejection and elevated risk of rejection in kidney transplant patients.